论文部分内容阅读
目的探讨微生态制剂(培菲康)联合思密达治疗新生儿轮状病毒性肠炎的临床疗效。方法对90例新生儿轮状病毒性肠炎患儿随机分为3组,在液疗、纠酸等治疗基础上,A组加用培菲康治疗,B组加用思密达治疗,C组加用培菲康联合思密达治疗,比较三组临床疗效。结果A、B、C组的总有效率分别为63·33%、66·67%、93·33%,平均止泻时间分别为(75·21±3·28)h、(73·33±5·05)h、(57·51±5·72)h。无论总有效率或平均止泻时间,C组与A组或B组相比,差异均有显著性(P<0·05或<0·01)。结论微生态制剂(培菲康)联合思密达治疗新生儿轮状病毒性肠炎的疗效肯定,值得临床推广使用。
Objective To investigate the clinical efficacy of probiotics combined with smecta in the treatment of neonatal rotavirus enteritis. Methods Ninety cases of newborns with rotavirus enteritis were randomly divided into three groups. On the basis of liquid therapy and acid correction, the patients in group A were treated with Pefikan, while those in group B were treated with metmyme and those in group C Plus Peifu Kang combined with Smectite treatment, the clinical efficacy of the three groups were compared. Results The total effective rates in groups A, B and C were 63.33%, 66.67% and 93.33%, respectively, and the average effective time of antidiarrheal were (75.21 ± 3.28) h and (73.33 ± 5.05) h, (57.51 ± 5.72) h. There was significant difference (P <0.05 or <0.01) between group C and group A or group B, regardless of the total effective rate or mean time to antidiarrheal. Conclusion Microecological agents (Peifu Kang) combined with Smecta treatment of neonatal rotavirus enteritis positive effect, worthy of clinical promotion and use.